Questionnaire Outline: Ig Demand Quant Immunoglobulin 211235 December 06, 2021

LRW Study Name: Ig Demand Quant Immunoglobulin
LRW Job Number: 211235

Date: December 06, 2021
The contents of this document are the confidential property of Lieberman Research Worldwide. No part of this document may be
reproduced or distributed in any form without the express written permission of Lieberman Research Worldwide.
QUESTIONNAIRE OUTLINE
Hold CTRL and click on a question to jump there

Screener.......................................................................................................................................................................................................................3
DV_TargetPanel...................................................................................................................................................................................................3
DT_Intro................................................................................................................................................................................................................3
S1_AE_Reporting.................................................................................................................................................................................................3
S2_SensitiveIndustry............................................................................................................................................................................................3
S4_BoardCertProfession......................................................................................................................................................................................4
S5_Conditions.......................................................................................................................................................................................................4
DV_ConditionsXSpecialty.....................................................................................................................................................................................5
DV_SpecialtyQuota...............................................................................................................................................................................................5
S6_StatePracticeIn...............................................................................................................................................................................................6
S7_Tenure............................................................................................................................................................................................................6
S8_DirectPatientCare...........................................................................................................................................................................................7
S9_PatientsYear...................................................................................................................................................................................................7
S10_PatientsTreated............................................................................................................................................................................................7
DV_NeuroPtsTreatSum........................................................................................................................................................................................7
DV_CaptureNumPtTreat.......................................................................................................................................................................................8
DV_CaptureNumPtTreatGBS...............................................................................................................................................................................8
DV_PercentofPatientSeen....................................................................................................................................................................................8
S11_PrescribeIg...................................................................................................................................................................................................9
S12_GBSPrescribeIg..........................................................................................................................................................................................10
DV_CountNeuroPtsOnIG....................................................................................................................................................................................10
S13_PracticeSetting...........................................................................................................................................................................................10
Screener terminations............................................................................................................................................................................................11
A. Current Patient Landscape and General Treatment Attitudes..............................................................................................................................12
DV_InsertCondition.............................................................................................................................................................................................12
DT_AIntro............................................................................................................................................................................................................12
A1_DiagnoseRefer..............................................................................................................................................................................................12
A2_ReferredSpecialty.........................................................................................................................................................................................13
A3_PISeverity.....................................................................................................................................................................................................13
A4_PortionMisdiagnosed....................................................................................................................................................................................13
A5_TimeToDiagnosis..........................................................................................................................................................................................14
A6_PortionUndiagnosed.....................................................................................................................................................................................14
A7_UndiagnosedReasons..................................................................................................................................................................................15
A8_NewPatientTrend..........................................................................................................................................................................................15
A9_PtIncreaseReasons......................................................................................................................................................................................15
A10_ExpectedPtChangeYrs...............................................................................................................................................................................16
A11_BipolarChoosingTx.....................................................................................................................................................................................16
A12_BipolarIgTx.................................................................................................................................................................................................17
B. Current Treatment Algorithm.................................................................................................................................................................................18
DT_BIntro............................................................................................................................................................................................................18
Loop Start - Pre_Allocation_Loop..........................................................................................................................................................................18
DV_LoopNumPatients........................................................................................................................................................................................18
B1_PreAllocation................................................................................................................................................................................................19
DV_PreAllocationSum........................................................................................................................................................................................20
B2_IgAcuteMaintenceTx.....................................................................................................................................................................................20
B3_WhyNotUseIg100P.......................................................................................................................................................................................20
B4_AvgIgAdmin..................................................................................................................................................................................................21
B5_IgEfficacySatisfact........................................................................................................................................................................................22
C. Ig Deep Dive..........................................................................................................................................................................................................23
DT_CIntro............................................................................................................................................................................................................23
C1_IgRxChange.................................................................................................................................................................................................23
C2_PercIgIncreased...........................................................................................................................................................................................23
C3_IgIncreaseReasons......................................................................................................................................................................................23
C4_PercIgDecrease............................................................................................................................................................................................23
C5_IgDecreaseReasons.....................................................................................................................................................................................24
C6_PtsDiscontinueIg..........................................................................................................................................................................................24
C7_DiscontinueTime...........................................................................................................................................................................................25
C8_IgDrugHoliday...............................................................................................................................................................................................25
C9_IgDrugHolidayLength...................................................................................................................................................................................26
C10_AvgTimePtonIg...........................................................................................................................................................................................26
LRW # 211235 © 2021 LRW. All rights reserved. CONFIDENTIAL. 1

DV_ControlledDefinition......................................................................................................................................................................................27
C11_PtsControlledonIg.......................................................................................................................................................................................27
C12_ROATxPlan................................................................................................................................................................................................28
C13_IV_SC_SwitchRsns....................................................................................................................................................................................28
C14_SC_IV_SwitchRsns....................................................................................................................................................................................29
C15_IVIG_SiteofCare.........................................................................................................................................................................................29
C16_SCIG_SiteOfCare.......................................................................................................................................................................................30
C17_SCIGNonHomeHome.................................................................................................................................................................................31
D. Future Treatment Algorithm & Anti FcRn Reactions.............................................................................................................................................32
DT_DIntro............................................................................................................................................................................................................32
D1_FutureSCIGUse............................................................................................................................................................................................32
D2_IncreaseSCIGReasons................................................................................................................................................................................32
Subsection Start - TPP + DCM for Neuro & ITP....................................................................................................................................................32
DT_TPPIntro.......................................................................................................................................................................................................32
D3_TPP_Appeal.................................................................................................................................................................................................33
D4_IntentToPrescribeTPP..................................................................................................................................................................................33
D5_PatientTypeTPP...........................................................................................................................................................................................34
D6_StartSwitchTPP............................................................................................................................................................................................34
D7_TimeToIncorporate.......................................................................................................................................................................................34
E. Demographics........................................................................................................................................................................................................35
DT_DemoIntro....................................................................................................................................................................................................35
E1_Gender..........................................................................................................................................................................................................35
E2_Hispanic........................................................................................................................................................................................................35
E3_Ethnicity........................................................................................................................................................................................................35
DV_EthnicityNet..................................................................................................................................................................................................35
E4_PtGender......................................................................................................................................................................................................36
E5_PtAge............................................................................................................................................................................................................36
E6_PtEthnicity.....................................................................................................................................................................................................37
E7_PtEmployment..............................................................................................................................................................................................37
E8_PtInsurance..................................................................................................................................................................................................38
E9_PediatricIG....................................................................................................................................................................................................38
QC Flags....................................................................................................................................................................................................................39
Appendix - Logic Rule Descriptions...........................................................................................................................................................................40

SCREENER
- Programmer: Please only allow these devices into the survey: PC, Tablet, Smartphone.
[DV_TargetPanel]
- Hidden Question. Show to all.
DV_TargetPanel. Hidden variable to capture if link is from client list or panel
Select one response.
DEFAULT ORDER.
1. Target
2. Panel
[Intro]
- Show to all.
DT_Intro We appreciate your interest in our survey. Please be assured that this survey is completely confidential, and we will only use this
. information for research purposes. Your confidentiality is our priority and your name will not be passed on to the sponsoring
company.
We will start by asking you a few preliminary questions to confirm the relevance of our survey to you. Once you have completed
the preliminary questions, you will be taken through the remainder of the study.
Simply answer each question by clicking inside the appropriate box. During the survey please do not use your browser's forward
and back buttons. Instead please use the NEXT button below to move through the survey.
This material is non promotional, confidential and is for Market Research purposes only.
[AE_Reporting]
- Show to all.
- Terminate Immediately if respondent selected code [NotWantProceed] at S1_AE_Reporting.
S1_AE_Reporting. We are required to pass on to the sponsor details of adverse events that are mentioned during the course of market
research. Should you mention an adverse event in a specific patient during the survey, we will need to report this event
even if you have already reported it directly to the company or the regulatory authorities. In such a situation you will be
asked to waive confidentiality in relation to that adverse event. Everything else you write during the course of the survey
will continue to remain confidential. If you wish, you may remain anonymous in the report. Thank you for your
assistance.
Please indicate how you would like to proceed:

DEFAULT ORDER.
1. I would like to proceed and give permission to disclose
my contact details to the sponsor. I understand that I may
be contacted by the sponsor if I share information about
an Adverse Event, and the sponsor may pass my details
on to a regulatory authority
2. I would like to proceed but wish to remain anonymous
3. I do not want to proceed Terminate immediately.
[SensitiveIndustry]
- Show to all.
- Terminate Immediately if respondent selected any codes [GovernmentMedicalRev, MarketingMRDepartmen,
HealthcareCommunicat, MemberDrugApproval, PaidInvestigatorRese] at S2_SensitiveIndustry.
S2_SensitiveIndustry. Are you, or any member of your immediate family, currently employed by any of the following?
DEFAULT ORDER.
1. The government medical review agency Terminate immediately.
2. A marketing or market research department or company Terminate immediately.
3. A healthcare communication agency Terminate immediately.
4. Member of any drug approval body, e.g. FDA (US) Terminate immediately.
5. Paid investigator, researcher or consultant (other than Terminate immediately.
participating in clinical trials) for a pharmaceutical
company or healthcare manufacturer
99. None of the above

[BoardCertProfession]
- Show to all.
- Terminate Immediately if respondent selected any codes [GeneralPractitioner, PrimaryCarePractitioner, Rheumatologist,
InfectiousDisease, NursePractitioner, PhysicianAssistant, RegisteredNurse, OtherSpec, NotBoardCertified] at
S4_BoardCertProfession.
S4_BoardCertProfession. Which, if any of these, represents the field where you have board certification?
RANDOMIZE LIST.
RANDOMIZE WITHIN.
1. General Practitioner (GP) Terminate immediately.
2. Primary Care Practitioner (PCP) Terminate immediately.
RANDOMIZE WITHIN.
3. Neuromuscular Specialist
4. Neurologist
5. Allergist / Immunologist
6. Hematologist / Oncologist
7. Rheumatologist Terminate immediately.
8. Infectious Disease Terminate immediately.
9. Nurse Practitioner (NP) Terminate immediately.
10. Physician Assistant (PA) Terminate immediately.
11. Registered Nurse (RN) Terminate immediately.
98. Other ANCHOR. Terminate immediately.
99. I am not board certified ANCHOR. Terminate immediately.
[Conditions]
- Show to all.
- Terminate Immediately if respondent did NOT select codes [PI, CIDP, MG, GBS, MMN, ITP] at S5_Conditions.
- Programmer Comment: Lock stubs 6 & 12 and randomize within.
S5_Conditions. What types of conditions do you have experience in diagnosing or treating?
Select all that apply.
RANDOMIZE LIST.
1. Primary Immunodeficiency (PI)
2. Chronic Inflammatory Demyelinating Polyneuropathy
(CIDP)
3. Myasthenia Gravis (MG)
4. Guillain-Barré Syndrome (GBS)
5. Multifocal Motor Neuropathy (MMN)
6. Chronic and Persistent Primary Immune
Thrombocytopenia (ITP)
7. Inflammatory Bowel Disorder (IBD)
8. Multiple Sclerosis (MS)
9. Eczema
10. Allergies
11. Lupus
12. Acute Episodic Immune Thrombocytopenia (ITP)
98. Other ANCHOR.
99. None of the above ANCHOR. EXCLUSIVE.

[DV_ConditionsXSpecialty]
- Hidden Question. Applies to all.
- Terminate Immediately if respondent selected code [OtherSpec] at DV_ConditionsXSpecialty.
DV_ConditionsXSpecialty. capturing condition alignment with specialty
DEFAULT ORDER.
1. Neurologist/Neuromuscular Specialist - CIDP Autocode if respondent selected code [CIDP] at
S5_Conditions AND respondent selected any
codes [NeuromuscularSpecialist, Neurologist] at
2. Neurologist/Neuromuscular Specialist - MG Autocode if respondent selected code [MG] at
3. Neurologist/Neuromuscular Specialist - GBS Autocode if respondent selected code [GBS] at
4. Neurologist/Neuromuscular Specialist - MMN Autocode if respondent selected code [MMN] at
5. Allergist/Immunologist Autocode if respondent selected code [PI] at
S5_Conditions AND respondent selected code
[AllergistImmunologist] at
6. Hematologist/Oncologist Autocode if respondent selected code [ITP] at
S5_Conditions AND respondent selected code
[HemOnc] at S4_BoardCertProfession.
7. Other Autocode if respondent did NOT select codes
[Neurologist_CIDP, Allergistimmunologis,
HemOnc] at DV_ConditionsXSpecialty
Terminate immediately.
[DV_SpecialtyQuota]
DV_SpecialtyQuota. capturing total specialty
DEFAULT ORDER.
1. Neurologist/Neuromuscular Specialist Autocode if respondent selected any codes
[Neurologist_CIDP, Neurologist_MG,
Neurologist_GBS, Neurologist_MMN] at
DV_ConditionsXSpecialty.
2. Allergist/Immunologist Autocode if respondent selected code
[Allergistimmunologis] at
DV_ConditionsXSpecialty.
3. Hematologist/Oncologist Autocode if respondent selected code [HemOnc]
at DV_ConditionsXSpecialty.

[StatePracticeIn]
- Show to all.
- Terminate Immediately if respondent selected code [VT] at S6_StatePracticeIn.
S6_StatePracticeIn. Please specify the state in which you primarily practice.
Select one response from the drop-down box.
DEFAULT ORDER.
1. Alabama
2. Alaska
3. Arizona
4. Arkansas
5. California
6. Colorado
7. Connecticut
8. Delaware
9. Florida
10. Georgia
11. Hawaii
12. Idaho
13. Illinois
14. Indiana
15. Iowa
16. Kansas
17. Kentucky
18. Louisiana
19. Maine
20. Maryland
21. Massachusetts
22. Michigan
23. Minnesota
24. Mississippi
25. Missouri
26. Montana
27. Nebraska
28. Nevada
29. New Hampshire
30. New Jersey
31. New Mexico
32. New York
33. North Carolina
34. North Dakota
35. Ohio
36. Oklahoma
37. Oregon
38. Pennsylvania
39. Rhode Island
40. South Carolina
41. South Dakota
42. Tennessee
43. Texas
44. Utah
45. Vermont Terminate immediately.
46. Virginia
47. Washington
48. Washington D.C.
49. West Virginia
50. Wisconsin
51. Wyoming
[Tenure]
- Show to all.
- Terminate Immediately if value provided at S7_Tenure is less than 5 OR value provided at S7_Tenure is greater than 35.
S7_Tenure. For how many years have you been in practice in your current specialty?
Enter a numeric response.
MIN: 0. MAX: 100. INTEGER NUMERIC RESPONSES.

[DirectPatientCare]
- Show to all.
- Terminate Immediately if value provided at S8_DirectPatientCare is less than 75.
S8_DirectPatientCare. What percentage of time do you spend in clinical practice or direct patient care? That is, seeing and treating
patients, as opposed to teaching, research, or administration.
% MIN: 0. MAX: 100. INTEGER NUMERIC RESPONSES.
[PatientsYear]
- Show to all.
- Terminate Immediately if value provided at S9_PatientsYear is less than 100.
S9_PatientsYear. In the past year, about how many patients did you personally see in your primary practice / teleconference for any
reason?
patients MIN: 0. MAX: 5000. INTEGER NUMERIC RESPONSES.
[PatientsTreated]
- Show to all.
- Each column must be less than or equal to 'response at S9_PatientsYear'
- Terminate Immediately if (respondent selected code [Allergistimmunologis] at DV_ConditionsXSpecialty AND any row [Treat] at
S10_PatientsTreated, the value in any column [PI] is less than 5) OR (respondent selected code [HemOnc] at
DV_ConditionsXSpecialty AND any row [Treat] at S10_PatientsTreated, the value in any column [ITP] is less than 5).
S10_PatientsTreated. In the past year, about how many adult (18+) patients did you personally treat or manage for the following
condition(s)?
As a reminder, you mentioned you personally see [Insert response from PatientsYear] patients in your primary
practice / teleconference.
Enter numeric responses.
Chronic Chronic
Inflammato and
ry Persistent
Demyelinat Primary
ing Guillain- Multifocal Immune
Primary Polyneuro Myastheni Barré Motor Thromboc
COLS: RANDOMIZE LIST. Immunodef pathy a Gravis Syndrome Neuropath ytopenia
ROWS: RANDOMIZE LIST. iciency (PI) (CIDP) (MG) (GBS) y (MMN) (ITP)
1. # Treat or manage [1] [2] [3] [4] [5] [6]
MIN: 0. MAX: MIN: 0. MAX: MIN: 0. MAX: MIN: 0. MAX: MIN: 0. MAX: MIN: 0. MAX:
300. 300. 300. 300. 300. 300.
INTEGER INTEGER INTEGER INTEGER INTEGER INTEGER
NUMERIC NUMERIC NUMERIC NUMERIC NUMERIC NUMERIC
RESPONSE RESPONSE RESPONSE RESPONSE RESPONSE RESPONSE
S. Show if S. Show if S. Show if S. Show if S. Show if S. Show if
respondent respondent respondent respondent respondent respondent
selected selected selected selected selected selected
code code code code code code
[Allergistim [Neurologist [Neurologist [Neurologist [Neurologist [HemOnc] at
munologis] _CIDP] at _MG] at _GBS] at _MMN] at DV_Conditio
at DV_Conditio DV_Conditio DV_Conditio DV_Conditio nsXSpecialt
DV_Conditio nsXSpecialt nsXSpecialt nsXSpecialt nsXSpecialt y. PC: Max
nsXSpecialt y. PC: Max y. PC: Max y. PC: Max y. PC: Max Input = 200
y. PC: Max Input = 100 Input = 100 Input = 100 Input = 100
Input = 300
[DV_NeuroPtsTreatSum]
- Hidden Question. Applies if respondent selected any codes [Neurologist_CIDP, Neurologist_MG, Neurologist_GBS,
Neurologist_MMN] at DV_ConditionsXSpecialty.
- Terminate Immediately if value provided at DV_NeuroPtsTreatSum is less than 5.
DV_NeuroPtsTreatSum. Sum Neuro Patients Treating Across CIDP, MG, GBS, MMN
[Insert response from PatientsTreated.Treat.CIDP] + [Insert response from PatientsTreated.Treat.MG] + [Insert
response from PatientsTreated.Treat.GBS] + [Insert response from PatientsTreated.Treat.MMN]

[DV_CaptureNumPtTreat]
- Hidden Question. Applies if respondent selected any codes [Neurologist_CIDP, Neurologist_MG, Neurologist_MMN,
Allergistimmunologis, HemOnc] at DV_ConditionsXSpecialty.
DV_CaptureNumPtTreat. Capture Number of Patients Treated Per Condition
DEFAULT ORDER.
1. [Insert response from PatientsTreated.Treat.PI] PI Autocode if any row [Treat] at
Patients S10_PatientsTreated, the value in any column [PI]
is greater than 0.
2. [Insert response from PatientsTreated.Treat.CIDP] Autocode if any row [Treat] at
CIDP Patients S10_PatientsTreated, the value in any column
[CIDP] is greater than 0.
3. [Insert response from PatientsTreated.Treat.MG] MG Autocode if any row [Treat] at
Patients S10_PatientsTreated, the value in any column
[MG] is greater than 0.
4. [Insert response from PatientsTreated.Treat.MMN] Autocode if any row [Treat] at
MMN Patients S10_PatientsTreated, the value in any column
[MMN] is greater than 0.
5. [Insert response from PatientsTreated.Treat.ITP] ITP Autocode if any row [Treat] at
Patients S10_PatientsTreated, the value in any column
[ITP] is greater than 0.
[DV_CaptureNumPtTreatGBS]
- Hidden Question. Applies if respondent selected code [Neurologist_GBS] at DV_ConditionsXSpecialty.
DV_CaptureNumPtTreatGBS. Capture Number of Patients Treated For GBS
DEFAULT ORDER.
1. [Insert response from PatientsTreated.Treat.GBS] Autocode if any row [Treat] at
GBS Patients S10_PatientsTreated, the value in any column
[GBS] is greater than 0.
[DV_PercentofPatientSeen]
DV_PercentofPatientSeen. Hidden variable to capture the number of condition patients seen over total.
COLS: DEFAULT ORDER.

ROWS: DEFAULT ORDER. Percent
1. Percent of PI Patients
[1] PC: CALCULATION – % of Patients Treated for PI over Total Patients Seen
Seen
2. Percent of CIDP
[1] PC: CALCULATION – % of Patients Treated for CIDP over Total Patients Seen
Patients Seen
3. Percent of MG Patients
[1] PC: CALCULATION – % of Patients Treated for MG over Total Patients Seen
Seen
4. Percent of GBS
[1] PC: CALCULATION – % of Patients Treated for GBS over Total Patients Seen
Patients Seen
5. Percent of MMN
[1] PC: CALCULATION – % of Patients Treated for MMN over Total Patients Seen
Patients Seen
6. Percent of ITP Patients
[1] PC: CALCULATION – % of Patients Treated for ITP over Total Patients Seen
Seen
MIN: 0. MAX:
100.
INTEGER
NUMERIC
RESPONSE
S.

[PrescribeIg]
- Show if any row [Treat] at S10_PatientsTreated, the value in any column [PI, CIDP, MG, MMN, ITP] is greater than 0.
- Terminate Immediately if any row [TreatedIg] at S11_PrescribeIg, the value in any column [PI] is less than 5 OR any row
[TreatedIg] at S11_PrescribeIg, the value in any column [ITP] is less than 5.
- Programmer Comment: Validation logic: The answers must be less than or equal to the corresponding answers in
S10_PatientsTreated
S11_PrescribeIg. In the past year, for how many of your adult (18+) patients with the following condition(s) are treated
with immunoglobulin (Ig) therapy?
You mentioned that you treat:
 [Insert response from DV_CaptureNumPtTreat]
Chronic Chronic
Inflammato and
ry Persistent
Demyelinat Primary
1. # treated with Ig therapy [1] [2] [3] [4] [5] [6]
300. 300. 300. 300. 300. 300.
S. Show if S. Show if S. Show if S. PC: HIDE S. Show if S. Show if
any row any row any row STUB any row any row
[Treat] at [Treat] at [Treat] at [Treat] at [Treat] at
S10_Patient S10_Patient S10_Patient S10_Patient S10_Patient
sTreated, sTreated, sTreated, sTreated, sTreated,
the value in the value in the value in the value in the value in
any column any column any column any column any column
[PI] is [CIDP] is [MG] is [MMN] is [ITP] is
greater than greater than greater than greater than greater than
0. PC: Max 0. PC: Max 0. PC: Max 0. PC: Max 0. PC: Max
Input = 300 Input = 100 Input = 100 Input = 100 Input = 200

[GBSPrescribeIg]
- Show if any row [Treat] at S10_PatientsTreated, the value in any column [GBS] is greater than 0.
- Programmer Comment: Validation logic: The answers must be less than or equal to the corresponding answers in
S10_PatientsTreated
S12_GBSPrescribeIg. In the past year, for how many of your adult (18+) patients with Guillain-Barré Syndrome (GBS) have ever been
on or are currently on immunoglobulin (Ig) therapy?
You mentioned that you treat:
 [Insert response from DV_CaptureNumPtTreatGBS]
Chronic Chronic
Inflammato and
ry Persistent
Demyelinat Primary
1. # Ever been on or
[1] [2] [3] [4] [5] [6]
currently on Ig therapy
100. 100. 100. 100. 100. 100.
S. PC: HIDE S. PC: HIDE S. PC: HIDE S. Show if S. PC: HIDE S. PC: HIDE
STUB STUB STUB any row STUB STUB
[Treat] at
S10_Patient
sTreated,
the value in
any column
[GBS] is
greater than
0.
[DV_CountNeuroPtsOnIG]
- Hidden Question. Applies if respondent selected any codes [Neurologist_CIDP, Neurologist_MG, Neurologist_GBS,
Neurologist_MMN] at DV_ConditionsXSpecialty.
- Terminate Immediately if value provided at DV_CountNeuroPtsOnIG is less than 5.
DV_CountNeuroPtsOnIG. Sum Neuro Patients On IG Therapy
[Insert response from PrescribeIg.TreatedIg.CIDP] + [Insert response from PrescribeIg.TreatedIg.MG] +
[Insert response from PrescribeIg.TreatedIg.MMN] + [Insert response from
GBSPrescribeIg.EverBeenCurrentlyOnIg.GBS]
- Programmer: Need to add DVs for:

CALCULATION – % of Patients Prescribed Ig over Patients Treated for PI
CALCULATION – % of Patients Prescribed Ig over Patients Treated for CIDP
CALCULATION – % of Patients Prescribed Ig over Patients Treated for MG
CALCULATION – % of Patients Prescribed Ig over Patients Treated for GBS
CALCULATION – % of Patients Prescribed Ig over Patients Treated for MMN
CALCULATION – % of Patients Prescribed Ig over Patients Treated for ITP
[PracticeSetting]
- Show to all.
- Terminate Immediately if respondent selected code [OtherSpec] at S13_PracticeSetting.
S13_PracticeSetting. Which best describes your primary practice setting?
RANDOMIZE LIST.
1. A hospital
2. A private office

3. A clinic / infusion clinic
98. Other ANCHOR. Terminate immediately.

Screener terminations
Question number Termination logic statement Termination type

S1_AE_Reporting Terminate Immediately if respondent selected code Immediately
[NotWantProceed] at S1_AE_Reporting
S2_SensitiveIndustry Terminate Immediately if respondent selected any codes Immediately
[GovernmentMedicalRev, MarketingMRDepartmen,
HealthcareCommunicat, MemberDrugApproval,
PaidInvestigatorRese] at S2_SensitiveIndustry
S4_BoardCertProfession Terminate Immediately if respondent selected any codes Immediately
[GeneralPractitioner, PrimaryCarePractitioner, Rheumatologist,
InfectiousDisease, NursePractitioner, PhysicianAssistant,
RegisteredNurse, OtherSpec, NotBoardCertified] at
S4_BoardCertProfession
S5_Conditions Terminate Immediately if respondent did NOT select codes [PI, Immediately
CIDP, MG, GBS, MMN, ITP] at S5_Conditions
DV_ConditionsXSpecialty Terminate Immediately if respondent selected code [OtherSpec] at Immediately
DV_ConditionsXSpecialty
S6_StatePracticeIn Terminate Immediately if respondent selected code [VT] at Immediately
S6_StatePracticeIn
S7_Tenure Terminate Immediately if value provided at S7_Tenure is less than Immediately
5 OR value provided at S7_Tenure is greater than 35
S8_DirectPatientCare Terminate Immediately if value provided at S8_DirectPatientCare Immediately
is less than 75
S9_PatientsYear Terminate Immediately if value provided at S9_PatientsYear is Immediately
less than 100
S10_PatientsTreated Terminate Immediately if (respondent selected code Immediately
[Allergistimmunologis] at DV_ConditionsXSpecialty AND any row
[Treat] at S10_PatientsTreated, the value in any column [PI] is
less than 5) OR (respondent selected code [HemOnc] at
DV_ConditionsXSpecialty AND any row [Treat] at
S10_PatientsTreated, the value in any column [ITP] is less than 5)
DV_NeuroPtsTreatSum Terminate Immediately if value provided at Immediately
DV_NeuroPtsTreatSum is less than 5
S11_PrescribeIg Terminate Immediately if any row [TreatedIg] at S11_PrescribeIg, Immediately
the value in any column [PI] is less than 5 OR any row [TreatedIg]
at S11_PrescribeIg, the value in any column [ITP] is less than 5
DV_CountNeuroPtsOnIG Terminate Immediately if value provided at Immediately
DV_CountNeuroPtsOnIG is less than 5
S13_PracticeSetting Terminate Immediately if respondent selected code [OtherSpec] at Immediately
S13_PracticeSetting

A. CURRENT PATIENT LANDSCAPE AND GENERAL TREATMENT ATTITUDES
[DV_InsertCondition]
DV_InsertCondition. Punch what conditions respondents are treating from S11.PatientsTreated. If multiple conditions are punched,
separate by a comma with the last condition preceded by an 'and'.
RANDOMIZE LIST.
1. Primary Immunodeficiency (PI) Autocode if any row [Treat] at
S10_PatientsTreated, the value in any column [PI]
is greater than 0.
2. Chronic Inflammatory Demyelinating Polyneuropathy Autocode if any row [Treat] at
(CIDP) S10_PatientsTreated, the value in any column
[CIDP] is greater than 0.
3. Myasthenia Gravis (MG) Autocode if any row [Treat] at
S10_PatientsTreated, the value in any column
[MG] is greater than 0.
4. Guillain-Barré Syndrome (GBS) Autocode if any row [Treat] at
[GBS] is greater than 0.
5. Multifocal Motor Neuropathy (MMN) Autocode if any row [Treat] at
[MMN] is greater than 0.
6. Chronic and Persistent Primary Immune Autocode if any row [Treat] at
Thrombocytopenia (ITP) S10_PatientsTreated, the value in any column
[ITP] is greater than 0.
[AIntro]
- Show to all.
DT_AIntro. Thank you for participating in this survey! The following questions pertain to your experiences diagnosing and treating your
patients with [Insert response from DV_InsertCondition].
[DiagnoseRefer]
- Show to all. Only show column stubs selected at DV_InsertCondition.
- Programmer Comment: The answers must be less than or equal to the corresponding answers in S10_PatientsTreated
A1_DiagnoseRefer. In the past year, about how many adult (18+) patients did you personally diagnose or were referred to you with a
diagnosis for the following condition(s)?
As a reminder, you mentioned you treat:

Chronic Chronic
Inflammato and
ry Persistent
Demyelinat Primary
1. # Personally diagnosed [1] [2] [3] [4] [5] [6]
2. # Referred to with a
[1] [2] [3] [4] [5] [6]
diagnosis
400. 400. 400. 400. 400. 400.
S. S. S. S. S. S.

[ReferredSpecialty]
- Show if any row [ReferredDiagnosis] at A1_DiagnoseRefer, the value in any column [PI, CIDP, MG, GBS, MMN, ITP] is greater than
0.
A2_ReferredSpecialty. You mentioned that some of your patients were referred to you with a diagnosis, from which specialty was this?
RANDOMIZE LIST.
1. General Practitioner (GP)
2. Primary Care Practitioner (PCP)
3. ER Doctor
4. Rheumatologist
5. Infectious Disease
6. Otolaryngologist (ENT)
98. Other ANCHOR.
[PISeverity]
- Show if respondent selected code [PI] at DV_InsertCondition.
- Each column must be equal to '100'
- Show running total for each column.
A3_PISeverity. Thinking about your [Insert response from DV_CaptureNumPtTreat] that you treat, what portion are mild, moderate, or
severe?
Column must sum to 100%
COLS: DEFAULT ORDER. % of

ROWS: DEFAULT ORDER. Patients
1. Mild [1]
2. Moderate [1]
3. Severe [1]
MIN: 0. MAX:
100.
INTEGER
NUMERIC
RESPONSE
S.
[PortionMisdiagnosed]
A4_PortionMisdiagnosed. Sometimes, symptoms of [Insert response from DV_InsertCondition] are misidentified as another disease.
What portion of your patients received a different diagnosis prior to their official diagnosis?

Chronic Chronic
Inflammato and
ry Persistent
Demyelinat Primary
ROWS: DEFAULT ORDER. iciency (PI) (CIDP) (MG) (GBS) y (MMN) (ITP)
1. % Misdiagnosed [1] [2] [3] [4] [5] [6]
100. 100. 100. 100. 100. 100.
S. S. S. S. S. S.

[TimeToDiagnosis]
- Answer by column.
A5_TimeToDiagnosis. Thinking about your [Insert response from DV_InsertCondition] patients, on average, how long does it take them
to receive an official diagnosis - starting from when their first symptoms present and ending with their final
diagnosis?
Select one response for each.
Chronic Chronic
Inflammato and
ry Persistent
Demyelinat Primary
1. Less than 1 month 1 2 3 4 5 6
2. 1 to 3 months 1 2 3 4 5 6
3. 4 to 6 months 1 2 3 4 5 6
4. 7 to 9 months 1 2 3 4 5 6
5. 10 to 12 months 1 2 3 4 5 6
6. 1 to 2 years 1 2 3 4 5 6
7. 3 to 4 years 1 2 3 4 5 6
8. 5 to 6 years 1 2 3 4 5 6
9. More than 7 years 1 2 3 4 5 6
[PortionUndiagnosed]
A6_PortionUndiagnosed. Generally in the US, what portion of [Insert response from DV_InsertCondition] patients do you estimate
never receive a formal diagnosis for their [Insert response from DV_InsertCondition] because it remains
undiagnosed or undetected?
Chronic Chronic
Inflammato and
ry Persistent
Demyelinat Primary
1. % Undiagnosed [1] [2] [3] [4] [5] [6]
100. 100. 100. 100. 100. 100.
S. S. S. S. S. S.

[UndiagnosedReasons]
- Show if any row [Undiagnosed] at A6_PortionUndiagnosed, the value in any column [PI, CIDP, MG, GBS, MMN, ITP] is greater than
0.
A7_UndiagnosedReasons. Why do you think these patients go undiagnosed?
RANDOMIZE LIST.
1. Patients think that symptoms will eventually go away, so
they do not visit a doctor
2. Doctor thinks symptoms are less severe, so they only
treat the symptoms and don't make a diagnosis
3. Patients fear going to the doctor since COVID
4. Patients mistake their symptoms for something else
5. Disease diagnosis guidelines are not commonly known
6. Diagnosis criteria is one of exclusion
7. Condition symptoms are often secondary symptoms of
other diagnoses
8. Health professionals have very minimal experience
identifying these conditions
9. Symptom presentation varies considerably across
patients
10. Patients' socioeconomic status
11. Patients' race and ethnicity
12. Patients' education
98. Other ANCHOR.
[NewPatientTrend]
- Answer by column.
A8_NewPatientTrend. In the past year, how has the number of new patients you've seen with [Insert response from DV_InsertCondition]
changed, if at all?
Chronic Chronic
Inflammato and
ry Persistent
Demyelinat Primary
1. Increased a lot 1 2 3 4 5 6
2. Increased a little 1 2 3 4 5 6
3. Stayed the same 1 2 3 4 5 6
4. Decreased a little 1 2 3 4 5 6
5. Decreased a lot 1 2 3 4 5 6
[PtIncreaseReasons]
- Show if, for any column at A8_NewPatientTrend, the respondent selected any codes [IncreasedAlot, IncreasedLittle].
A9_PtIncreaseReasons. Why has the number of [Insert response from DV_InsertCondition] patients been increasing?
RANDOMIZE LIST.
DEFAULT ORDER.
1. Increased HCP awareness of condition
2. Increased patient awareness of condition
3. Surge of patients who put-off going to the doctor during
COVID
4. More patients are presenting with the disease (incidence
increasing)
5. The ability to diagnose condition is easier (prevalence
increasing)
6. Better testing for conditions (i.e. antibody tests)
7. Standardized diagnosing criteria
8. Inherited patients from other physicians
98. Other ANCHOR.

[ExpectedPtChangeYrs]
A10_ExpectedPtChangeYrs. In the next 5 years, how many more new patients associated with [Insert response from
DV_InsertCondition] do you expect to see and treat?
If you expect no new patients (your amount of patients to remain the same as now) enter '0'.

Chronic Chronic
Inflammato and
ry Persistent
Demyelinat Primary
2. In 5 years [1] [2] [3] [4] [5] [6]
300. 300. 300. 300. 300. 300.
S. S. S. S. S. S.
[BipolarChoosingTx]
- Show to all.
A11_BipolarChoosingTx. How would you describe your attitudes about treating [Insert response from DV_InsertCondition]?
RANDOMIZE LIST.
Somewhat Somewhat
Much More More More Much More
1. I prefer to stay with I am ready to adopt new
established therapies until therapies immediately
1 2 3 4
new therapies become when they become
standard of care available
I actively advocate for my
2. I'd rather use therapies
patients to make sure they
already on the formulary or
get coverage as quickly as
wait for insurance 1 2 3 4
possible if they are
coverage to start treatment
uninsured or are not
for a patient
covered for the treatment
3. I focus more on I focus more on patient
insurance coverage when 1 2 3 4 burden when selecting a
selecting a therapy therapy
When deciding on
4. When deciding on
treatment, I offer patients
treatment, I predominantly
1 2 3 4 options and we choose the
rely on my prior experience
best course of treatment
and treatment guidelines
together
5. I focus more on patient I focus more on treatment
tolerance when selecting a 1 2 3 4 efficacy when selecting a
therapy therapy
6. I tend to focus more on
I make a significant effort
the patient's disease, their
1 2 3 4 to get a holistic view of a
symptoms and how their
patient’s life
symptoms impact them

[BipolarIgTx]
- Show to all.
A12_BipolarIgTx. How would you describe your attitudes about treating [Insert response from DV_InsertCondition] with Ig therapy?
RANDOMIZE LIST.
Somewhat Somewhat
Much More More More Much More
Some patients outcomes
1. I have total confidence
might be better when they
when Immunoglobulin (Ig)
1 2 3 4 are given the flexibility of
is administered at an
having Immunoglobulin (Ig)
infusion center
at home
2. SCIG treatments with SCIG treatments with less
more frequent frequent administration
1 2 3 4
administration have better have equally good
outcomes outcomes
I am comfortable if the
3. I like to specify the Ig
1 2 3 4 pharmacist selects which
brand used for treatment
Ig brand to dispense
4. When choosing an Ig
treatment, I consider how When choosing an Ig
much the treatment will 1 2 3 4 treatment, I consider how
interfere with my patient's effective it will be
life
5. I prefer to start patients I am comfortable starting
1 2 3 4
on IVIG my patients on SCIG
6. I prefer patients starting
I prefer patients starting on
on SCIG in an infusion 1 2 3 4
SCIG at home
clinic

B. CURRENT TREATMENT ALGORITHM
[BIntro]
- Show to all.
DT_BIntro. Thank you for your answers so far! The following questions aim to understand your current treatment experience and outlook
when treating patients with [Insert response from DV_InsertCondition].
Loop Start - Pre_Allocation_Loop
[Pre_Allocation_Loop]
- Only show row stubs selected at DV_InsertCondition.
Pre_Allocation_Loop. Pre_Allocation_Loop
Iterations:
RANDOMIZE LIST.
1. Primary Immunodeficiency (PI)
2. Chronic Inflammatory Demyelinating Polyneuropathy
(CIDP)
3. Myasthenia Gravis (MG)
4. Guillain-Barré Syndrome (GBS)
5. Multifocal Motor Neuropathy (MMN)
6. Chronic and Persistent Primary Immune
Thrombocytopenia (ITP)
Questions:
[DV_LoopNumPatients]
DV_LoopNumPatients. Capture Number of Patients Treated Per Condition To Insert In Loop
DEFAULT ORDER.
1. [Insert response from PatientsTreated.Treat.PI] PI Autocode if respondent is in any of these
Patients iterations [PI].
2. [Insert response from PatientsTreated.Treat.CIDP] Autocode if respondent is in any of these
CIDP Patients iterations [CIDP].
3. [Insert response from PatientsTreated.Treat.MG] MG Autocode if respondent is in any of these
Patients iterations [MG].
6. [Insert response from PatientsTreated.Treat.GBS] Autocode if respondent is in any of these
GBS Patients iterations [GBS].
4. [Insert response from PatientsTreated.Treat.MMN] Autocode if respondent is in any of these
MMN Patients iterations [MMN].
5. [Insert response from PatientsTreated.Treat.ITP] ITP Autocode if respondent is in any of these
Patients iterations [ITP].

[PreAllocation]
- Show to all.
B1_PreAllocation. Of your [Insert current iteration] patients, what percent do you prescribe each of the following as a primary treatment
for the condition?
 [Insert response from DV_LoopNumPatients]
Rows 1-7: RANDOMIZE WITHIN. Header: CIDP, MMN, GBS, MG. Show if respondent is in any of these iterations [CIDP, MG, GBS, MMN]
Rows 8-9: RANDOMIZE WITHIN. Header: PI. Show if respondent is in any of these iterations [PI]
Rows 10-19: RANDOMIZE WITHIN. Header: ITP. Show if respondent is in any of these iterations [ITP]

ROWS: RANDOMIZE LIST. Patients
1. IVIG [1]
2. SCIG [1]
3. Plasmapheresis [1]
4. Immunosuppressant
[1]
(i.e. Imuran)
5. Corticosteroid (i.e.
[1]
Prednisone)
6. Muscle Strengthener
[1]
(i.e. Mestinon)
7. Antibody Therapy (i.e.
[1]
Rituxan)
8. IVIG [1]
9. SCIG [1]
10. IVIG [1]
11. SCIG [1]
12. Blood Transfusion [1]
13. Plasmapheresis [1]
14. Immunosuppressant
[1]
(i.e. Imuran)
15. Corticosteroid (i.e.
[1]
Prednisone)
16. Muscle Strengthener
[1]
(i.e. Mestinon)
17. Antibody Therapy (i.e.
[1]
Rituxan)
18. Thrombopoietin
Receptor Antagonist (i.e. [1]
Promacta, Nplate)
19. Spleen tyrosine kinase
(SYK) inhibitor (i.e. [1]
Tavalisse)
98. Other treatment [1] ANCHOR.
99. No treatment (wait and
[1] ANCHOR.
see)
MIN: 0. MAX:
100.
INTEGER
NUMERIC
RESPONSE
S.

[DV_PreAllocationSum]
DV_PreAllocationSum. sum up %s:
- Ig therapy (IVIG + SCIG)
- Other (everything else + other (not including No Treatment))
- No treatment (wait and see)

ROWS: DEFAULT ORDER. Patients
1. Ig Therapy [1]
98. All other options [1] ANCHOR.
99. No treatment (wait and
[1] ANCHOR.
see)
MIN: 0. MAX:
100.
INTEGER
NUMERIC
RESPONSE
S.
[IgAcuteMaintenceTx]
- Show if any row [IgTherapy] at DV_PreAllocationSum, the value in any column [Num] is greater than 0.
B2_IgAcuteMaintenceTx. You mentioned that you use Ig therapy for your [Insert current iteration] patients. What portion of them are
prescribed Ig therapy for acute and maintenance treatments?

1. % of patients prescribed
Ig therapy for acute [1]
treatment
2. % of patients prescribed
Ig therapy for maintenance [1]
treatment
MIN: 0. MAX:
100.
INTEGER
NUMERIC
RESPONSE
S.
Loop End - Pre_Allocation_Loop
[WhyNotUseIg100P]
- Show if any row [IgTherapy] at DV_PreAllocationSum, the value in any column [Num] is less than 100 for any Iteration(s) [PI, CIDP,
MG, GBS, MMN, ITP].
B3_WhyNotUseIg100P. You reported that you do not always use Ig therapy to treat your [Insert response from DV_InsertCondition]
patients. Why do you not use Ig therapy for some patients?
RANDOMIZE LIST.
1. Ig therapy is used more for patients with severe
symptoms
2. There is a lack of supply or stocking of Ig therapy
3. Older patients may find more efficacy in other treatments
RANDOMIZE WITHIN.
4. Ig therapy is not as efficacious as other treatments
5. Ig therapy is not as tolerable as other treatments
6. Patient comorbidities / contraindications (diabetes,
cardiac issues, kidney problems, etc.)
7. Volume of dosage is too high
8. Does not fit the patient’s lifestyle (not as convenient as
other therapies)
9. Insurance or cost issues
10. Not FDA approved for an indication
98. Other__________ ANCHOR.

[AvgIgAdmin]
- Show if any row [IgTherapy] at DV_PreAllocationSum, the value in any column [Num] is greater than or equal to 1 for any
Iteration(s) [PI, CIDP, MG, MMN, ITP].
B4_AvgIgAdmin. On average, what is the frequency of Ig administration for your [Insert response from DV_InsertCondition] patients?
Chronic Chronic
Inflammato and
ry Persistent
Demyelinat Primary
COLS: DEFAULT ORDER. Immunodef pathy a Gravis Syndrome Neuropath ytopenia
1. Weekly [1] [2] [3] [4] [5] [6]
2. Every 2 weeks [1] [2] [3] [4] [5] [6]
3. Every 3 weeks [1] [2] [3] [4] [5] [6]
4. Monthly [1] [2] [3] [4] [5] [6]
5. Every 2 Months [1] [2] [3] [4] [5] [6]
6. Every 3 months [1] [2] [3] [4] [5] [6]
7. Less than every 3
[1] [2] [3] [4] [5] [6]
months
100. 100. 100. 100. 100. 100.
[IgTherapy] [IgTherapy] [IgTherapy] [IgTherapy] [IgTherapy]
at at at at at
DV_PreAlloc DV_PreAlloc DV_PreAlloc DV_PreAlloc DV_PreAlloc
ationSum, ationSum, ationSum, ationSum, ationSum,
[Num] is [Num] is [Num] is [Num] is [Num] is
0 for any 0 for any 0 for any 0 for any 0 for any
Iteration(s) Iteration(s) Iteration(s) Iteration(s) Iteration(s)
[PI]. [CIDP]. [MG]. [MMN]. [ITP].

[IgEfficacySatisfact]
- Show if any row [IgTherapy] at DV_PreAllocationSum, the value in any column [Num] is greater than 0 for any Iteration(s) [PI,
CIDP, MG, GBS, MMN, ITP].
- Answer by column.
B5_IgEfficacySatisfact. How satisfied are you with the efficacy of Ig therapy?
Chronic Chronic
Inflammato and
ry Persistent
Demyelinat Primary
1. Very unsatisfied 1 2 3 4 5 6
2. Somewhat unsatisfied 1 2 3 4 5 6
3. Neither satisfied nor
1 2 3 4 5 6
unsatisfied
4. Somewhat satisfied 1 2 3 4 5 6
5. Very satisfied 1 2 3 4 5 6
Show if any Show if any Show if any Show if any Show if any Show if any
row row row row row row
[IgTherapy] [IgTherapy] [IgTherapy] [IgTherapy] [IgTherapy] [IgTherapy]
at at at at at at
DV_PreAlloc DV_PreAlloc DV_PreAlloc DV_PreAlloc DV_PreAlloc DV_PreAlloc
ationSum, ationSum, ationSum, ationSum, ationSum, ationSum,
the value in the value in the value in the value in the value in the value in
any column any column any column any column any column any column
[Num] is [Num] is [Num] is [Num] is [Num] is [Num] is
greater than greater than greater than greater than greater than greater than
0 for any 0 for any 0 for any 0 for any 0 for any 0 for any
Iteration(s) Iteration(s) Iteration(s) Iteration(s) Iteration(s) Iteration(s)
[PI]. [CIDP]. [MG]. [GBS]. [MMN]. [ITP].

C. IG DEEP DIVE
[CIntro]
- Show to all.
DT_CIntro. Now we would like to understand your attitudes and prescribing behaviors for Ig therapy specifically.
[IgRxChange]
C1_IgRxChange. How has your prescribing behavior for Ig changed in the past year?
DEFAULT ORDER.
1. Increased a lot
2. Increased somewhat
3. Stayed the same
4. Decreased somewhat
5. Decreased a lot
[PercIgIncreased]
- Show if respondent selected any codes [IncreasedLot, IncreasedSome] at C1_IgRxChange.
C2_PercIgIncreased. By what portion has your Ig therapy prescribing increased in the past year?
[IgIncreaseReasons]
- Show if respondent selected any codes [IncreasedLot, IncreasedSome] at C1_IgRxChange.
C3_IgIncreaseReasons. Why has your Ig prescribing behavior increased?
RANDOMIZE LIST.
1. COVID influenced more Ig use due to a lack of hospital
bed availability (i.e. outpatient treatment)
2. FDA approved Ig therapy for more indications
3. SCIG provides more convenience for patient
4. Increase in clinical trials proving good efficacy and safety
for Ig therapy
5. Increase in diagnoses requiring Ig therapy
6. Ig therapy has become the standard of care
7. Ig therapy is more readily available
8. Patient race and ethnicity demographics of my practice
have changed
9. Patient socioeconomic demographics of my practice have
changed
98. Other ANCHOR.
[PercIgDecrease]
- Show if respondent selected any codes [DecreasedSome, DecreasedLot] at C1_IgRxChange.
C4_PercIgDecrease. By what portion has your Ig therapy prescribing decreased in the past year?

[IgDecreaseReasons]
- Show if respondent selected any codes [DecreasedSome, DecreasedLot] at C1_IgRxChange.
C5_IgDecreaseReasons. Why has your Ig prescribing behavior decreased?
RANDOMIZE LIST.
1. There is a lack of supply and stocking of Ig therapy
2. There are less patients going to the doctor due to COVID
3. There are less patients with conditions requiring Ig
therapy
4. Other treatment options work better
5. Insurance or cost issues
6. Fewer people are getting sick due to recent COVID mask, Show if respondent selected code [PI] at
vaccination and safety protocols DV_InsertCondition.
98. Other ANCHOR.
[PtsDiscontinueIg]
CIDP, MG, MMN, ITP].
- Each column must be less than or equal to '100'
C6_PtsDiscontinueIg. What portion of your [Insert response from DV_InsertCondition] patients, if any, elect to discontinue their Ig
therapy?
If none, enter '0'.
Chronic Chronic
Inflammato and
ry Persistent
Demyelinat Primary
1. % of Patients Electing
[1] [2] [3] [4] [5] [6]
to Discontinue Ig Therapy
100. 100. 100. 100. 100. 100.
at at at at at

[DiscontinueTime]
- Show if any row [PatientsDiscontinue] at C6_PtsDiscontinueIg, the value in any column [PI, CIDP, MG, MMN, ITP] is greater than 0.
- Answer by column.
C7_DiscontinueTime. You mentioned that some of your patients elect to discontinue their Ig therapy. Typically, after how long on Ig
therapy do they discontinue their treatment?
Chronic Chronic
Inflammato and
ry Persistent
Demyelinat Primary
1. Less than 1 year 1 2 3 4 5 6
2. 1 - 2 years 1 2 3 4 5 6
3. 3 - 5 years 1 2 3 4 5 6
4. 6 - 10 years 1 2 3 4 5 6
5. More than 10 years 1 2 3 4 5 6
Show if any Show if any Show if any PC: HIDE Show if any Show if any
row row row STUB row row
[PatientsDis [PatientsDis [PatientsDis [PatientsDis [PatientsDis
continue] at continue] at continue] at continue] at continue] at
C6_PtsDisco C6_PtsDisco C6_PtsDisco C6_PtsDisco C6_PtsDisco
ntinueIg, the ntinueIg, the ntinueIg, the ntinueIg, the ntinueIg, the
value in any value in any value in any value in any value in any
column [PI] column column [MG] column column [ITP]
is greater [CIDP] is is greater [MMN] is is greater
than 0. greater than than 0. greater than than 0.
0. 0.
[IgDrugHoliday]
- Each column must be less than or equal to '100'
C8_IgDrugHoliday. What portion of your [Insert response from DV_InsertCondition] patients, if any, elect to take a 'drug holiday' from Ig
therapy?
If none, enter '0'.
Chronic Chronic
Inflammato and
ry Persistent
Demyelinat Primary
1. % of Patients Taking a
'Drug Holiday' from Ig [1] [2] [3] [4] [5] [6]
Therapy
100. 100. 100. 100. 100. 100.
at at at at at

[IgDrugHolidayLength]
- Show if any row [PatientsDrugHoliday] at C8_IgDrugHoliday, the value in any column [PI, CIDP, MG, MMN, ITP] is greater than 0.
- Answer by column.
C9_IgDrugHolidayLength. You mentioned that some of your patients elect to take a 'drug holiday' from their Ig therapy. Typically, how long
does their drug holiday last?
Chronic Chronic
Inflammato and
ry Persistent
Demyelinat Primary
1. Less than 1 month 1 2 3 4 5 6
2. 1 to 3 months 1 2 3 4 5 6
3. 4 to 6 months 1 2 3 4 5 6
4. 7 to 9 months 1 2 3 4 5 6
5. 10 to 12 months 1 2 3 4 5 6
6. More than 1 year 1 2 3 4 5 6
[PatientsDru [PatientsDru [PatientsDru [PatientsDru [PatientsDru
gHoliday] at gHoliday] at gHoliday] at gHoliday] at gHoliday] at
C8_IgDrugH C8_IgDrugH C8_IgDrugH C8_IgDrugH C8_IgDrugH
oliday, the oliday, the oliday, the oliday, the oliday, the
value in any value in any value in any value in any value in any
column [PI] column column [MG] column column [ITP]
is greater [CIDP] is is greater [MMN] is is greater
than 0. greater than than 0. greater than than 0.
0. 0.
[AvgTimePtonIg]
- Answer by column.
C10_AvgTimePtonIg. What is the average time a [Insert response from DV_InsertCondition] patient is on Ig therapy?
Chronic Chronic
Inflammato and
ry Persistent
Demyelinat Primary
1. Less than 1 year 1 2 3 4 5 6
2. 1 - 2 years 1 2 3 4 5 6
3. 3 - 5 years 1 2 3 4 5 6
4. 6 – 10 years 1 2 3 4 5 6
5. Patients are always on
1 2 3 4 5 6
Ig therapy
at at at at at

[DV_ControlledDefinition]
DV_ControlledDefinition. Punch Controlled Definition Per Condition Treating
DEFAULT ORDER.
1. PI: controlled = no breakthrough infections Autocode if any row [IgTherapy] at
DV_PreAllocationSum, the value in any column
[Num] is greater than 0 for any Iteration(s) [PI].
4. CIDP: controlled = improved function Autocode if any row [IgTherapy] at
[Num] is greater than 0 for any Iteration(s) [CIDP].
2. MG: controlled = improved muscle function and no Autocode if any row [IgTherapy] at
breathing/swallowing problems DV_PreAllocationSum, the value in any column
[Num] is greater than 0 for any Iteration(s) [MG].
5. GBS: controlled = full recovery after treatment Autocode if any row [IgTherapy] at
[Num] is greater than 0 for any Iteration(s) [GBS].
3. MMN: controlled = improved muscle strength Autocode if any row [IgTherapy] at
[Num] is greater than 0 for any Iteration(s) [MMN].
6. ITP: controlled = normal platelet levels/treatment-free Autocode if any row [IgTherapy] at
remission DV_PreAllocationSum, the value in any column
[Num] is greater than 0 for any Iteration(s) [ITP].
[PtsControlledonIg]
C11_PtsControlledonIg. What percent of your [Insert response from DV_InsertCondition] patients are successfully controlled on Ig
therapy? By controlled, we mean:
 [Insert response from DV_ControlledDefinition]
Chronic Chronic
Inflammato and
ry Persistent
Demyelinat Primary
1. % Controlled on Ig
[1] [2] [3] [4] [5] [6]
Therapy
100. 100. 100. 100. 100. 100.
any row any row any row any row any row any row
at at at at at at

[ROATxPlan]
C12_ROATxPlan. Approximately what percentage of your [Insert response from DV_InsertCondition] patients treated with Ig therapy
have followed the following treatment plans?
Chronic Chronic
Inflammato and
ry Persistent
Demyelinat Primary
1. % Start on IVIG and
[1] [2] [3] [4] [5] [6]
stay on IVIG
2. % Start on IVIG and
[1] [2] [3] [4] [5] [6]
switch to SCIG
3. % Start on SCIG and
[1] [2] [3] [4] [5] [6]
stay on SCIG
4. % Start on SCIG and
[1] [2] [3] [4] [5] [6]
switch to IVIG
100. 100. 100. 100. 100. 100.
at at at at at at
[IV_SC_SwitchRsns]
- Show if any row [IVIG_SCIG] at C12_ROATxPlan, the value in any column [PI, CIDP, MG, GBS, MMN, ITP] is greater than 0.
C13_IV_SC_SwitchRsns. Why have some patients started on IVIG and switched to SCIG?
RANDOMIZE LIST.
RANDOMIZE WITHIN.
1. Patient preference
2. My preference
3. Insurance coverage / access challenges
4. Patient wanted the convenience of self-administering at
home
5. Patient couldn’t tolerate IVIG
98. Other ANCHOR.

[SC_IV_SwitchRsns]
- Show if any row [SCIG_IVIG] at C12_ROATxPlan, the value in any column [PI, CIDP, MG, GBS, MMN, ITP] is greater than 0.
C14_SC_IV_SwitchRsns. Why have some patients started on SCIG and switched to IVIG?
RANDOMIZE LIST.
RANDOMIZE WITHIN.
1. Patient preference
2. My preference
3. Insurance coverage / access challenges
4. Patient wanted HCP administration / in-center
administration
5. Patient wasn’t complying with administration
6. Patient couldn’t tolerate SCIG
98. Other ANCHOR.
[IVIG_SiteofCare]
- Show if any row [Ivig_NEURO, Ivig_PI, Ivig_ITP] at B1_PreAllocation, the value in any column [Num] is greater than 0 for any
Iteration(s) [PI, CIDP, MG, GBS, MMN, ITP].
C15_IVIG_SiteofCare. Approximately what percentage of your [Insert response from DV_InsertCondition] patients treated with IVIG
therapy are administering in the following settings?
Chronic Chronic
Inflammato and
ry Persistent
Demyelinat Primary
1. % Home based IVIG [1] [2] [3] [4] [5] [6]
2. % Infusion center/clinics
[1] [2] [3] [4] [5] [6]
IVIG
3. % Hospital setting IVIG [1] [2] [3] [4] [5] [6]
100. 100. 100. 100. 100. 100.
[Ivig_PI] at [Ivig_NEUR [Ivig_NEUR [Ivig_NEUR [Ivig_NEUR [Ivig_ITP] at
B1_PreAlloc O] at O] at O] at O] at B1_PreAlloc
ation, the B1_PreAlloc B1_PreAlloc B1_PreAlloc B1_PreAlloc ation, the
value in any ation, the ation, the ation, the ation, the value in any
column value in any value in any value in any value in any column
[Num] is column column column column [Num] is
greater than [Num] is [Num] is [Num] is [Num] is greater than
0 for any greater than greater than greater than greater than 0 for any
Iteration(s) 0 for any 0 for any 0 for any 0 for any Iteration(s)
[PI]. Iteration(s) Iteration(s) Iteration(s) Iteration(s) [ITP].
[CIDP]. [MG]. [GBS]. [MMN].

[SCIG_SiteOfCare]
- Show if any row [Scig_NEURO, SCIG_PI, Scig_ITP] at B1_PreAllocation, the value in any column [Num] is greater than 0 for any
Iteration(s) [PI, CIDP, MG, GBS, MMN, ITP].
C16_SCIG_SiteOfCare. Approximately what percentage of your [Insert response from DV_InsertCondition] patients treated with SCIG
therapy are administering in the following settings?
Chronic Chronic
Inflammato and
ry Persistent
Demyelinat Primary
1. % Home based SCIG [1] [2] [3] [4] [5] [6]
2. % Infusion center/clinics
[1] [2] [3] [4] [5] [6]
SCIG
3. % Hospital setting SCIG [1] [2] [3] [4] [5] [6]
100. 100. 100. 100. 100. 100.
[SCIG_PI] at [Scig_NEUR [Scig_NEUR [Scig_NEUR [Scig_NEUR [Scig_ITP] at
B1_PreAlloc O] at O] at O] at O] at B1_PreAlloc
ation, the B1_PreAlloc B1_PreAlloc B1_PreAlloc B1_PreAlloc ation, the
value in any ation, the ation, the ation, the ation, the value in any
column value in any value in any value in any value in any column
[Num] is column column column column [Num] is
greater than [Num] is [Num] is [Num] is [Num] is greater than
0 for any greater than greater than greater than greater than 0 for any
Iteration(s) 0 for any 0 for any 0 for any 0 for any Iteration(s)
[PI]. Iteration(s) Iteration(s) Iteration(s) Iteration(s) [ITP].
[CIDP]. [MG]. [GBS]. [MMN].

[SCIGNonHomeHome]
- Show if any row [HomeBased_SCIG] at C16_SCIG_SiteOfCare, the value in any column [PI, CIDP, MG, MMN, ITP] is greater than 0.
C17_SCIGNonHomeHome. Approximately what percentage of your [Insert response from DV_InsertCondition] patients treated with in-
home SCIG therapy are starting their loading dose in non-home (i.e. infusion center/clinic or hospital setting)
then moving to home?
Chronic Chronic
Inflammato and
ry Persistent
Demyelinat Primary
1. % Starting SCIG in non-
home then moving to in- [1] [2] [3] [4] [5] [6]
home
2. % Starting SCIG in-
[1] [2] [3] [4] [5] [6]
home and staying in-home
100. 100. 100. 100. 100. 100.
[HomeBased [HomeBased [HomeBased [HomeBased [HomeBased
_SCIG] at _SCIG] at _SCIG] at _SCIG] at _SCIG] at
C16_SCIG_S C16_SCIG_S C16_SCIG_S C16_SCIG_S C16_SCIG_S
iteOfCare, iteOfCare, iteOfCare, iteOfCare, iteOfCare,
[PI] is [CIDP] is [MG] is [MMN] is [ITP] is
0. 0. 0. 0. 0.

D. FUTURE TREATMENT ALGORITHM & ANTI FCRN REACTIONS
[DIntro]
- Show to all.
DT_DIntro Now we would like to understand how your treatment plan for [Insert response from DV_InsertCondition] patients may
. change in the future.
[FutureSCIGUse]
- Answer by column.
D1_FutureSCIGUse. In the next year, how do you think your SCIG use will change?
Chronic Chronic
Inflammato and
ry Persistent
Demyelinat Primary
1. Increase a lot 1 2 3 4 5 6
2. Increase a little 1 2 3 4 5 6
3. Stay the same 1 2 3 4 5 6
4. Decrease a little 1 2 3 4 5 6
5. Decrease a lot 1 2 3 4 5 6
[IncreaseSCIGReasons]
- Show if, for any column [PI, CIDP, MG, GBS, MMN, ITP] at D1_FutureSCIGUse, the respondent selected any codes [IncreaseLot,
IncreaseLittle].
D2_IncreaseSCIGReasons. Why do you intend to use more SCIG in the future?
RANDOMIZE LIST.
1. Anticipate payers to make me prescribe SCIG for cost
benefits
2. Patients are requesting it more
3. More brands are in the market
4. FDA approves it for more indications
5. Recommendation from another healthcare professional
6. Patient want more convenience for their infusions to be at
home
98. Other ANCHOR.
- Programmer: Link to DCM: XXX

Question text to use with DCM tasks: Out of the products shown, please select which one you would prefer to use with
your PI patients.
Subsection Start - TPP + DCM for Neuro & ITP

Show if respondent selected any codes [CIDP, MG, GBS, MMN, ITP] at DV_InsertCondition
[TPPIntro]
- Show if respondent selected any codes [CIDP, MG, GBS, MMN, ITP] at DV_InsertCondition.
DT_TPPIntro. SHOW MOA TPP
- Programmer: Link to DCM: XXX

Question text to use with DCM tasks: Out of the products shown, please select which one you would prefer to use with
your patients.

[TPP_Appeal]
- Only show column stubs selected at DV_InsertCondition.
- Answer by column.
D3_TPP_Appeal. On a scale from 1 to 5, to what extent does Product X advance treatment for appropriate patients?
Chronic Chronic
Inflammato and
ry Persistent
Demyelinat Primary
1. 1 - Does not advance
1 2 3 4 5 6
treatment
2. 2 1 2 3 4 5 6
3. 3 1 2 3 4 5 6
4. 4 1 2 3 4 5 6
5. 5 - Advances treatment
1 2 3 4 5 6
extremely
PC: HIDE
STUB
[IntentToPrescribeTPP]
- Answer by column.
D4_IntentToPrescribeTPP. How likely, if at all, would you be to prescribe Product X to your patients?
Chronic Chronic
Inflammato and
ry Persistent
Demyelinat Primary
1. Definitely would not
1 2 3 4 5 6
prescribe
2. Probably would not
1 2 3 4 5 6
prescribe
3. Might or might not
1 2 3 4 5 6
prescribe
4. Probably would
1 2 3 4 5 6
prescribe
5. Definitely would
1 2 3 4 5 6
prescribe
PC: HIDE
STUB

[PatientTypeTPP]
D5_PatientTypeTPP. What type of patient would you use Product X for?
RANDOMIZE LIST.
RANDOMIZE WITHIN.
1. Older patient
2. Younger patient
3. Patient with comorbidities (diabetes, cardiac issues,
kidney problems, etc.)
DEFAULT ORDER.
4. Patient with mild to moderate symptoms
5. Patient with moderate to severe symtpoms
RANDOMIZE WITHIN.
6. New patient (with no prior treatment)
7. A patient not controlled on current therapy
98. Other ANCHOR.
[StartSwitchTPP]
- Answer by column.
D6_StartSwitchTPP. If Product X were available for use in the market, where would it generally fall in your treatment algorithm for your
patients?
Chronic Chronic
Inflammato and
ry Persistent
Demyelinat Primary
1. Product X would be the
first treatment I prescribe 1 2 3 4 5 6
for patients
2. Product X would be
1 2 3 4 5 6
used if Ig therapy fails
98. Somewhere else in my
1 2 3 4 5 6 ANCHOR.
treatment algorithm
PC: HIDE
STUB
[TimeToIncorporate]
D7_TimeToIncorporate. When do you think you would fully incorporate Product X, once approved, as part of your typical protocol for
treatment of [Insert response from DV_InsertCondition]?
DEFAULT ORDER.
1. Immediately, within 3 months
2. 3 to 6 months
3. 6 months to 1 year
4. 1 to 2 years
5. 2 to 3 years
6. 3 years or more
7. Would not prescribe or recommend
Subsection End - TPP + DCM for Neuro & ITP

E. DEMOGRAPHICS
[DemoIntro]
- Show to all.
DT_DemoIntro. You’re almost done! We have a few more questions left about you and your patient population.
[Gender]
- Show to all.
E1_Gender. Select your gender.
DEFAULT ORDER.
1. Male
2. Female
3. Non-binary / third gender
[Hispanic]
- Show to all.
E2_Hispanic. Are you of Hispanic or Latin American origin?
DEFAULT ORDER.
1. Yes, Hispanic
2. Yes, Latin American
3. No EXCLUSIVE.
[Ethnicity]
- Show to all.
E3_Ethnicity. Which of these categories describe you?
DEFAULT ORDER.
1. Asian
2. Black or African American
3. Middle Eastern or North African
4. Native American or Alaska Native
5. Pacific Islander or Native Hawaiian
6. White
7. Only Hispanic or Latin American origin EXCLUSIVE. Show if respondent selected any
codes [YesHispanic, YesLatinAmerican] at
E2_Hispanic.
[DV_EthnicityNet]
DV_EthnicityNet. Hidden variable to capture Ethnicity Net for weighting/quota.
DEFAULT ORDER.
1. Hispanic Autocode if respondent selected any codes
[YesHispanic, YesLatinAmerican] at E2_Hispanic.
2. Black or African-American Autocode if respondent selected code [AA] at
E3_Ethnicity AND respondent did NOT select code
[Hispanic] at DV_EthnicityNet.
3. Asian or Pacific Islander Autocode if respondent selected any codes
[Asian, PacIslanderHawaii] at E3_Ethnicity AND
respondent did NOT select codes [Hispanic, AA] at
DV_EthnicityNet.
4. Native American/Alaska Native Autocode if respondent selected code
[NativeAmerAlask] at E3_Ethnicity AND
respondent did NOT select codes [Hispanic, AA,
Asian] at DV_EthnicityNet.
5. Caucasian or White Autocode if respondent selected any codes
[MENA, White] at E3_Ethnicity AND respondent
did NOT select codes [Hispanic, AA, Asian,
NativeAmerAlask] at DV_EthnicityNet.

[PtGender]
E4_PtGender. What portion of your [Insert response from DV_InsertCondition] patient population falls into the following gender
categories?
Chronic Chronic
Inflammato and
ry Persistent
Demyelinat Primary
1. Male [1] [2] [3] [4] [5] [6]
2. Female [1] [2] [3] [4] [5] [6]
3. Non-binary / third
[1] [2] [3] [4] [5] [6]
gender
100. 100. 100. 100. 100. 100.
S. S. S. S. S. S.
[PtAge]
E5_PtAge. What portion of your [Insert response from DV_InsertCondition] patient population falls in the following age ranges?
Chronic Chronic
Inflammato and
ry Persistent
Demyelinat Primary
1. Under 18 [1] [2] [3] [4] [5] [6]
2. 18-25 [1] [2] [3] [4] [5] [6]
3. 26-34 [1] [2] [3] [4] [5] [6]
4. 35-44 [1] [2] [3] [4] [5] [6]
5. 45-54 [1] [2] [3] [4] [5] [6]
6. 55-64 [1] [2] [3] [4] [5] [6]
7. 65+ [1] [2] [3] [4] [5] [6]
100. 100. 100. 100. 100. 100.
S. S. S. S. S. S.

[PtEthnicity]
E6_PtEthnicity. What portion of your [Insert response from DV_InsertCondition] patient population can be classified in the following
race / ethnicities?
Chronic Chronic
Inflammato and
ry Persistent
Demyelinat Primary
1. Hispanic or Latino [1] [2] [3] [4] [5] [6]
2. Caucasian or White [1] [2] [3] [4] [5] [6]
3. African American or
[1] [2] [3] [4] [5] [6]
Black
4. Asian or Pacific Islander [1] [2] [3] [4] [5] [6]
5. Native American or
[1] [2] [3] [4] [5] [6]
Alaskan Native
6. Mixed Racial
[1] [2] [3] [4] [5] [6]
Background
7. Other [1] [2] [3] [4] [5] [6]
100. 100. 100. 100. 100. 100.
S. S. S. S. S. S.
[PtEmployment]
E7_PtEmployment. What portion of your patient population with [Insert response from DV_InsertCondition] fall into the following
employment types?
Chronic Chronic
Inflammato and
ry Persistent
Demyelinat Primary
1. Employed or Self-
[1] [2] [3] [4] [5] [6]
employed
2. Homemaker [1] [2] [3] [4] [5] [6]
3. Retired [1] [2] [3] [4] [5] [6]
4. Not currently employed [1] [2] [3] [4] [5] [6]
98. Not sure [1] [2] [3] [4] [5] [6]
100. 100. 100. 100. 100. 100.
S. S. S. S. S. S.

[PtInsurance]
E8_PtInsurance. What portion of your patient population with [Insert response from DV_InsertCondition] have the following insurance?
Chronic Chronic
Inflammato and
ry Persistent
Demyelinat Primary
1. Private / commercial
insurance (e.g. PPO, [1] [2] [3] [4] [5] [6]
HMO, etc.)
2. Medicare [1] [2] [3] [4] [5] [6]
3. Medicaid [1] [2] [3] [4] [5] [6]
4. Other gov't insurance
(e.g. Tri-care, Veteran's [1] [2] [3] [4] [5] [6]
Affairs, and Active Military)
5. Do not have insurance [1] [2] [3] [4] [5] [6]
6. Don't know the type of
[1] [2] [3] [4] [5] [6]
insurance they have
100. 100. 100. 100. 100. 100.
S. S. S. S. S. S.
[PediatricIG]
- Show to all.
- Programmer Comment: Include Opt out below numeric grid: 'I do not treat pediatric patients'
E9_PediatricIG. In the past year, what portion of your pediatric patients are treated with Ig therapy?
% of
COLS: DEFAULT ORDER. Pediatric
1. IVIG [1]
2. SCIG [1]
3. NOT on Ig Therapy [1] ANCHOR.
MIN: 0. MAX:
100.
INTEGER
NUMERIC
RESPONSE
S.

QC FLAGS
Terminate if respondent has accumulated at least 3 points.
Flag Type Apply To Rule Points

Timer Screener 5 Minutes 1
Timer Main + Screener 13 Minutes 1
Timer Question - A12_BipolarIgTx 12 Seconds 1
Programmer Comment Question - A12_BipolarIgTx Straightline 1
Timer Question - 12 Seconds 1
A11_BipolarChoosingTx
Programmer Comment Question - Straightline 1
A11_BipolarChoosingTx
Logical Question - C1_IgRxChange (respondent selected code 1
[IncreasedLot] at
C1_IgRxChange AND for any
column [PI, CIDP, MG, GBS,
MMN, ITP] at
A8_NewPatientTrend, the
respondent selected code
[DecreasedLot]) OR (respondent
selected code [DecreasedLot] at
C1_IgRxChange AND for any
MMN, ITP] at
A8_NewPatientTrend, the
[IncreasedAlot]).
Logical Question - (for any column [PI, CIDP, MG, 1
D4_IntentToPrescribeTPP GBS, MMN, ITP] at
D4_IntentToPrescribeTPP, the
[DefNotPrescribe] AND for any
MMN, ITP] at D3_TPP_Appeal,
the respondent selected code
[_5Advances]) OR (for any
MMN, ITP] at
D4_IntentToPrescribeTPP, the
[DefPrescribe] AND for any
MMN, ITP] at D3_TPP_Appeal,
the respondent selected code
[_1Not]).

APPENDIX - LOGIC RULE DESCRIPTIONS
Description Built Logic
Show to all Show to all
Show to all Show to all

Questionnaire Outline: Ig Demand Quant Immunoglobulin 211235 December 06, 2021

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Questionnaire Outline: Ig Demand Quant Immunoglobulin 211235 December 06, 2021

Uploaded by

Copyright:

Available Formats

LRW Study Name: Ig Demand Quant Immunoglobulin

LRW Job Number: 211235

Hold CTRL and click on a question to jump there

LRW # 211235 © 2021 LRW. All rights reserved. CONFIDENTIAL. 1

LRW # 211235 © 2021 LRW. All rights reserved. CONFIDENTIAL. 2

Please indicate how you would like to proceed:

LRW # 211235 © 2021 LRW. All rights reserved. CONFIDENTIAL. 3

LRW # 211235 © 2021 LRW. All rights reserved. CONFIDENTIAL. 4

LRW # 211235 © 2021 LRW. All rights reserved. CONFIDENTIAL. 5

MIN: 0. MAX: 100. INTEGER NUMERIC RESPONSES.

LRW # 211235 © 2021 LRW. All rights reserved. CONFIDENTIAL. 6

% MIN: 0. MAX: 100. INTEGER NUMERIC RESPONSES.

patients MIN: 0. MAX: 5000. INTEGER NUMERIC RESPONSES.

MIN: 0. MAX: 5000. INTEGER NUMERIC RESPONSES.

LRW # 211235 © 2021 LRW. All rights reserved. CONFIDENTIAL. 7

COLS: DEFAULT ORDER.

LRW # 211235 © 2021 LRW. All rights reserved. CONFIDENTIAL. 8

 [Insert response from DV_CaptureNumPtTreat]

Enter numeric responses.

LRW # 211235 © 2021 LRW. All rights reserved. CONFIDENTIAL. 9

 [Insert response from DV_CaptureNumPtTreatGBS]

Enter numeric responses.

MIN: 0. MAX: 400. INTEGER NUMERIC RESPONSES.

- Programmer: Need to add DVs for:

LRW # 211235 © 2021 LRW. All rights reserved. CONFIDENTIAL. 10

LRW # 211235 © 2021 LRW. All rights reserved. CONFIDENTIAL. 11

Question number Termination logic statement Termination type

LRW # 211235 © 2021 LRW. All rights reserved. CONFIDENTIAL. 12

 [Insert response from DV_CaptureNumPtTreat]

Enter numeric responses.

LRW # 211235 © 2021 LRW. All rights reserved. CONFIDENTIAL. 13

COLS: DEFAULT ORDER. % of

 [Insert response from DV_CaptureNumPtTreat]

Enter numeric responses.

LRW # 211235 © 2021 LRW. All rights reserved. CONFIDENTIAL. 14

LRW # 211235 © 2021 LRW. All rights reserved. CONFIDENTIAL. 15

LRW # 211235 © 2021 LRW. All rights reserved. CONFIDENTIAL. 16

As a reminder, you mentioned you treat:

 [Insert response from DV_CaptureNumPtTreat]

Enter numeric responses.

LRW # 211235 © 2021 LRW. All rights reserved. CONFIDENTIAL. 17

LRW # 211235 © 2021 LRW. All rights reserved. CONFIDENTIAL. 18

Loop Start - Pre_Allocation_Loop

LRW # 211235 © 2021 LRW. All rights reserved. CONFIDENTIAL. 19

As a reminder, you mentioned you treat:

 [Insert response from DV_LoopNumPatients]

Enter numeric responses.

COLS: DEFAULT ORDER. % of

LRW # 211235 © 2021 LRW. All rights reserved. CONFIDENTIAL. 20

COLS: DEFAULT ORDER. % of

COLS: DEFAULT ORDER. % of

Loop End - Pre_Allocation_Loop

LRW # 211235 © 2021 LRW. All rights reserved. CONFIDENTIAL. 21

LRW # 211235 © 2021 LRW. All rights reserved. CONFIDENTIAL. 22

LRW # 211235 © 2021 LRW. All rights reserved. CONFIDENTIAL. 23

MIN: 1. MAX: 100. INTEGER NUMERIC RESPONSES.

MIN: 1. MAX: 100. INTEGER NUMERIC RESPONSES.

LRW # 211235 © 2021 LRW. All rights reserved. CONFIDENTIAL. 24

LRW # 211235 © 2021 LRW. All rights reserved. CONFIDENTIAL. 25

LRW # 211235 © 2021 LRW. All rights reserved. CONFIDENTIAL. 26

LRW # 211235 © 2021 LRW. All rights reserved. CONFIDENTIAL. 27

 [Insert response from DV_ControlledDefinition]

Enter numeric responses.